InsidersTradesSigma
Vetoquinol SA Stock: price and directors' dealings · France · AMF
Follow the Vetoquinol SA share price and the full insider trade history of the company, a publicly traded company based in France. Shares are listed on FR FR, under the oversight of AMF. Operating in the Healthcare & Pharma sector, Vetoquinol SA has published 36 reports. Market capitalisation: €823m. The latest transaction was filed on 3 July 2026 (Acquisition). Among the most active insiders: SOPARFIN SCA SCA. The full history is accessible without an account.
36
Insider Decl.
0
Thresholds
€5m
20 ops.
Buy Volume
€3m
14 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Vetoquinol SA Buy (bullish), based on 4 analysts. Average price target: €90.38.
44Σ signal
Fundamental score
Ranked 1,947 of 25,898 companies
76.2
score / 100
Value74
Quality78
FCF yld6.2%
Earn yld6.9%
EV/EBITDA7.3x
ROE9.8%
Gross mgn75%
Net mgn11%
Debt/EBITDA0.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 3 July 2026
Declarations36 total
1,000 shares@ €71.150.0086% mcap9.9% of flowActionde gré à gré2026DD1124656
Ideal exit: 28 Mar 2027 (T+270)
1,000 shares@ €69.500.0082% mcap1.8% of flowActionde gré à gré2026DD1121792
Ideal exit: 14 Mar 2027 (T+270)
1,000 shares@ €69.500.0082% mcap2.8% of flowActionde gré à gré2026DD1121794
1,111 shares@ €86.502.6% of flowActionde gré à gré2026DD1092303
Ideal exit: 27 Oct 2026 (T+270)
4,930 shares@ €75.0015.3% of flowActionde gré à gré2025DD1047066
Ideal exit: 3 Apr 2026 (T+270)
4,930 shares@ €75.0057.4% of flowActionde gré à gré2025DD1047067
3,500 shares@ €78.4011.4% of flowActioncession de gré à gré2025DD1029915
3,500 shares@ €78.4042.6% of flowActionacquisition de gré à gré2025DD1029919
Ideal exit: 29 Dec 2025 (T+270)
2,000 shares@ €75.004.0% of flowActionacquisition de gré à gré2025DD1015324
Ideal exit: 10 Oct 2025 (T+270)
1,535 shares@ €84.003.4% of flowActionacquisition de gré à gré2024DD1007961
Ideal exit: 19 Aug 2025 (T+270)
500 shares@ €85.901.1% of flowActionacquisition de gré à gré2024DD999981
Ideal exit: 5 Jul 2025 (T+270)
4,000 shares@ €99.9010.7% of flowActionacquisition de gré à gré2024DD988655
Ideal exit: 21 Apr 2025 (T+270)
4,000 shares@ €99.9016.5% of flowActioncession de gré à gré2024DD988658
3,500 shares@ €99.0014.3% of flowActionDe gré à gré2024DD956882
3,500 shares@ €99.009.3% of flowActionDe gré à gré2024DD956883
Ideal exit: 16 Dec 2024 (T+270)
1,800 shares@ €101.604.9% of flowActionacquisition de gré à gré2024DD944555
Ideal exit: 29 Sept 2024 (T+270)
1,000 shares@ €87.503.6% of flowActionCession de gré à gré2023DD938591
1,000 shares@ €87.502.3% of flowActionacquisition de gré à gré2023DD938592
Ideal exit: 12 Aug 2024 (T+270)
400 shares@ €84.900.9% of flowActionacquisition de gré à gré2023DD927755
Ideal exit: 4 Jun 2024 (T+270)
1,500 shares@ €89.403.6% of flowActionacquisition de gré à gré2023DD878664
Ideal exit: 29 Sept 2023 (T+270)
5,500 shares0ActionHors plateforme de négociation2022DD844237
3,500 shares@ €129.5012.1% of flowActionAcquisition de gré à gré2022DD823744
Ideal exit: 18 Nov 2022 (T+270)
100 shares@ €126.6018.1% of flowActionEuronext Paris2022DD821285
130 shares@ €133.0024.7% of flowActionEuronext Paris2022DD821286
1,500 shares@ €132.005.3% of flowActionEuronext Paris2022DD814521
Ideal exit: 30 Sept 2022 (T+270)
25 of 36 declarations
About Vetoquinol SA
Vetoquinol SA is an independent veterinary pharmaceutical company focused on animal health. Listed on Euronext Paris since 2006 under the ticker VETO, the group serves two main end markets: companion animals, especially dogs and cats, and farm animals, notably cattle and pigs. Its business model covers the research, development, manufacturing and marketing of veterinary medicines as well as non-medicated products used to prevent, treat or support animal health conditions. In 2025, the company generated annual sales of €525.7 million, with a significant contribution from its Essentials portfolio, which has become a strategic engine for growth and profitability. Vetoquinol is therefore one of the leading international players in animal health, with operations across Europe, the Americas and Asia-Pacific. The company’s history dates back to 1933, when Joseph Frechin founded Vetoquinol in Lure, in eastern France. Since its origins, the group has followed a specialization strategy built around independence, scientific expertise and a strong veterinary focus. This family-rooted entrepreneurial background remains a core differentiator compared with many peers that are part of larger diversified pharmaceutical groups. Over time, Vetoquinol has expanded through a combination of targeted acquisitions, product innovation and international development, building a portfolio that is well established among veterinarians and animal owners. Vetoquinol markets solutions across several key therapeutic areas, including anti-infectives, anti-inflammatories, dermatology, pain management, locomotion, parasitology, reproduction and supportive care. The company addresses the everyday needs of veterinarians while also serving breeders and pet owners. A central pillar of the strategy is the “Essentials” category, made up of core products with strong recurring demand and potential to become market leaders. This segment supports revenue visibility and reflects the group’s emphasis on products with durable demand and broad clinical relevance. Vetoquinol also stands out for its commitment to innovation, customer proximity and local adaptation through a network of subsidiaries and distributors. Geographically, the group benefits from a diversified footprint that reduces exposure to any single market and helps balance business cycles across regions. This international presence supports resilience and provides access to markets with varying growth dynamics. Notable facts about Vetoquinol include its long operating history of more than 90 years, its status as a pure-play animal health specialist, and its position among the top global players in its industry. The company’s profile is also underpinned by favorable structural trends, such as rising veterinary care spending, increased pet ownership and the ongoing professionalization of livestock health management.
